BEPRIDIL

US Previously Marketed

First approved in 1990

Details

Stereochemistry	RACEMIC
Molecular Formula	C24H34N2O
Molecular Weight	366.5396
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)COCC(CN(CC1=CC=CC=C1)C2=CC=CC=C2)N3CCCC3

InChI

InChIKey=UIEATEWHFDRYRU-UHFFFAOYSA-N

InChI=1S/C24H34N2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C24H34N2O
Molecular Weight	366.5396
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.rxlist.com/vascor-drug.htm
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/mtm/bepridil.html | http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1075 | https://www.ncbi.nlm.nih.gov/pubmed/1280569

Bepridil is a calcium channel blocker that has well characterized anti-anginal properties and known but poorly characterized type 1 anti-arrhythmic and anti-hypertensive properties. It has inhibitory effects on both the slow calcium and fast sodium inward currents in myocardial and vascular smooth muscle, interferes with calcium binding to calmodulin, and blocks both voltage and receptor operated calcium channels. It is used to treat hypertension (high blood pressure), angina (chest pain), sustained atrial fibrillation and tachyarrhythmia. The most common side effects were upper gastrointestinal complaints (nausea, dyspepsia or GI distress), diarrhea, dizziness, asthenia and nervousness. Certain drugs could increase the likelihood of potentially serious adverse effects with bepridil hydrochloride. In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants. Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride. Cardiac glycosides could exaggerate the depression of AV nodal conduction observed with bepridil hydrochloride.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Beta-secretase (BACE) 5 Target ID: CHEMBL2111390 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20592218	Inhibitor 8504	6.0 µM [IC50]
Gamma-secretase 21 Target ID: CHEMBL2094135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20592218	Modulator 846
potassium sodium-activated channel subfamily T member 1 3 Target ID: 57582.0 Gene Symbol: KCNT1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16876206	Inhibitor 8504	1.0 µM [IC50]
Voltage and receptor operated calcium channels 3 Target ID: Voltage and receptor operated calcium channels Sources: http://www.rxlist.com/vascor-drug.htm	Blocker 555

Conditions

Condition	Modality	Highest Phase	Product
Chronic stable angina 10 Sources: http://www.rxlist.com/vascor-drug.htm	Primary	Approved 8583	BEPRICOR Approved Use Bepridil hydrochloride is indicated for the treatment of chronic stable angina (classic effort-associated angina).
Hypertension 575 Sources: https://www.drugs.com/mtm/bepridil.html	Primary	Approved 8583	BEPRICOR Approved Use Bepridil is used to treat hypertension (high blood pressure) and to treat angina (chest pain).
Atrial fibrillation 131 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1075	Primary	Approved 8583	BEPRICOR Approved Use It is usually used to treat sustained atrial fibrillation, tachyarrhythmia (ventricular) and angina.
Tachyarrhythmia 17 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1075	Primary	Approved 8583	BEPRICOR Approved Use It is usually used to treat sustained atrial fibrillation, tachyarrhythmia (ventricular) and angina.

C_max

Value	Dose	Co-administered	Analyte	Population
806 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7650227	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		BEPRIDIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
4.87 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7650227	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		BEPRIDIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
38.2 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7650227	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		BEPRIDIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
0.3% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3875635			BEPRIDIL plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
400 mg 1 times / day steady, oral Studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 34-77 years Health Status: unhealthy Age Group: 34-77 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	Disc. AE: Weakness, Lightheadedness... AEs leading to discontinuation/dose reduction: Weakness (2 patients) Lightheadedness (1 patient) Syncopal attack (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 39-84 years Health Status: unhealthy Age Group: 39-84 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	Disc. AE: Electrocardiogram QTc interval prolonged... AEs leading to discontinuation/dose reduction: Electrocardiogram QTc interval prolonged (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 43-80 years Health Status: unhealthy Age Group: 43-80 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	Disc. AE: Nausea, Diarrhea... AEs leading to discontinuation/dose reduction: Nausea (1 patient) Diarrhea (1 patient) Anorexia (1 patient) Bigeminy (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 63.5 years Health Status: unhealthy Age Group: 63.5 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	Disc. AE: Ventricular tachycardia, Bradycardia... AEs leading to discontinuation/dose reduction: Ventricular tachycardia (1 patient) Bradycardia (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 64.6 years Health Status: unhealthy Age Group: 64.6 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	Disc. AE: Ventricular tachycardia, Bradycardia... AEs leading to discontinuation/dose reduction: Ventricular tachycardia (grade 5, 1 patient) Bradycardia (1 patient) Electrocardiogram QTc interval prolonged (4 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/

AEs

AE	Significance	Dose	Population
Lightheadedness	1 patient Disc. AE	400 mg 1 times / day steady, oral Studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 34-77 years Health Status: unhealthy Age Group: 34-77 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Syncopal attack	1 patient Disc. AE	400 mg 1 times / day steady, oral Studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 34-77 years Health Status: unhealthy Age Group: 34-77 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Weakness	2 patients Disc. AE	400 mg 1 times / day steady, oral Studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 34-77 years Health Status: unhealthy Age Group: 34-77 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Electrocardiogram QTc interval prolonged	1 patient Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 39-84 years Health Status: unhealthy Age Group: 39-84 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Anorexia	1 patient Disc. AE	300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 43-80 years Health Status: unhealthy Age Group: 43-80 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Bigeminy	1 patient Disc. AE	300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 43-80 years Health Status: unhealthy Age Group: 43-80 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Diarrhea	1 patient Disc. AE	300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 43-80 years Health Status: unhealthy Age Group: 43-80 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Nausea	1 patient Disc. AE	300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 43-80 years Health Status: unhealthy Age Group: 43-80 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Bradycardia	1 patient Disc. AE	100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 63.5 years Health Status: unhealthy Age Group: 63.5 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/
Ventricular tachycardia	1 patient Disc. AE	100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 63.5 years Health Status: unhealthy Age Group: 63.5 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/
Bradycardia	1 patient Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 64.6 years Health Status: unhealthy Age Group: 64.6 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/
Electrocardiogram QTc interval prolonged	4 patients Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 64.6 years Health Status: unhealthy Age Group: 64.6 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/
Ventricular tachycardia	grade 5, 1 patient Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 64.6 years Health Status: unhealthy Age Group: 64.6 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252	inhibitor 2438	inhibitor 2507 substrate 1388

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2A6 879 CYP2E1 1060	CYP1A2 1197 P-gp 2052 BCRP 697

Drug as perpetrator

Target	Modality	Activity
CYP2A6 911	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11344532/	no
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11344532/	no
CYP2E1 1146	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11344532/	no
CYP3A4 2633	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11344532/	no
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/19702529/	yes
CYP2D6 2546	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/32906709/	yes

Drug as victim

Target	Modality	Activity
BCRP 697	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/28210973/	no
CYP1A2 1197	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/19196847/	yes
CYP2D6 1388	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/19196847/	yes
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/19196847/	yes
P-gp 2052	substrate 4014 Sources: https://www.futuremedicine.com/doi/abs/10.1517/14622416.2.4.401	yes

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY565364	https://www.001chemical.com/chem/64706-54-3
3B Scientific (Wuhan) Corp	3B2-0571	http://www.3bsc.com/index/pro_info.php?id=19927
abcr GmbH	AB542520	http://www.abcr.com/shop/en/AB542520
Achemo Scientific Limited	AC-11145	http://www.achemo.com/search/?Keyword=64706-54-3
AHH Chemical co.,ltd	API-1541	http://www.ahhchemical.com/product/API-1541.html
AK Scientific, Inc. (AKSCI)	K042	http://www.aksci.com/item_detail.php?cat=K042
Angel Pharmatech	AG121309	http://www.angelpharmatech.com/64706-54-3.html
BLD Pharm	BD116381	http://www.bldpharm.com/products/64706-54-3.html
ChemMol	30105085	http://www.chemmol.com/chemmol/30105085.html
ChemMol	99124623	http://www.chemmol.com/chemmol/99124623.html
Chemspace	CSSB00000047941	https://chem-space.com/CSSB00000047941
CSNpharm	CSN10416	https://www.csnpharm.com/products/bepridil.html
Debye Scientific	DB-054717	http://www.debyesci.com/cas_64706-54-3.html
Finetech	FT-0630749	http://www.finetechnology-ind.com/prod/detail/pub/64706-54-3.html
Glentham Life Sciences	GP4395	http://www.glentham.com/products/product/GP4395/
Lab Network	LN00330174	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00330174
Molcore	MC565364	https://www.molcore.com/product/64706-54-3
Smolecule	S520991	http://www.smolecule.com/products/s520991
Smolecule	S772535	https://www.smolecule.com/products/s772535
THE BioTek	bt-261730	https://www.thebiotek.com/product/inhibitors/bt-261730
THE BioTek	bt-311849	https://www.thebiotek.com/product/others/bt-311849
Vesino Industrial Co Ltd	VA10387	http://www.vsnchem.com/goto/product/23859/

PubMed

Title	Date	PubMed
Design, synthesis, and biological evaluation of novel T-Type calcium channel antagonists.	2004-07-16	15203145
Atrial fibrillatory frequency, atrial fibrillatory rate, or atrial cycle length--does it matter?	2004-07-01	15219531
Evidence for a protective role played by the Na+/Ca2+ exchanger in cerebral ischemia induced by middle cerebral artery occlusion in male rats.	2004-03	14975699
Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig.	2004-02-20	14975710
Bepridil block of recombinant human cardiac IKs current shows a time-dependent unblock.	2004-02	14716203
Bioequivalence study of two formulations of simvastatin tablets in healthy Thai volunteers.	2004	14979606
Slick (Slo2.1), a rapidly-gating sodium-activated potassium channel inhibited by ATP.	2003-12-17	14684870
A case of bepridil induced interstitial pneumonitis.	2003-12	14617550
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia.	2003-11-17	14612892
Role of Na(+)-Ca(2+) exchanger after traumatic or hypoxic/ischemic injury to spinal cord white matter.	2003-11-01	14588286
A case of sick sinus syndrome that developed torsades de pointes, pacing failure and sensing failure during administration of bepridil.	2003-09	14587660
Sodium-calcium exchange influences the response to endothelin-1 in lens epithelium.	2003-09	12887970
Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm.	2003-08-15	12914884
Transepithelial transport of bepridil in the human intestinal cell line, Caco-2, using a "dynamic model".	2003-07-25	12877575
Detection of proarrhythmia in the female rabbit heart: blinded validation.	2003-03	12716112
Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration.	2003-02	12557283
Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect.	2003-01	12687836
Evaluation of the effect of bepridil on paroxysmal atrial fibrillation: relationship between efficacy and the f-f interval in surface ECG recordings.	2003-01	12520144
Na+/Ca2+ exchanger in Na+ efflux-Ca2+ influx mode of operation exerts a neuroprotective role in cellular models of in vitro anoxia and in vivo cerebral ischemia.	2002-11	12502588
Beta-blocker decreases the increase in QT dispersion and transmural dispersion of repolarization induced by bepridil.	2002-11	12419934
Na(+)/Ca(2+) exchanger in porcine oocytes.	2002-10	12297528
[Successful hybrid therapy combined with oral bepridil and ICD in a patient with amiodarone refractory life-threatening ventricular tachyarrhythmia associated with ischemic cardiomyopathy].	2002-09-01	12235963
Possible role of calcium ions, calcium channels and calmodulin in excystation and metacystic development of Entamoeba invadens.	2002-09	12172816
Structure of the regulatory N-domain of human cardiac troponin C in complex with human cardiac troponin I147-163 and bepridil.	2002-08-23	12060657
Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression.	2002-08	12128170
Identification of radical scavengers in sweet grass (Hierochloe odorata).	2002-05-08	11982419
Assessment of pro-oxidant activity of foods by kinetic analysis of crocin bleaching.	2002-05-08	11982396
Antioxidant functions of selected allium thiosulfinates and S-alk(en)yl-L-cysteine sulfoxides.	2002-04-24	11958610
On-line HPLC-DPPH screening method for evaluation of radical scavenging phenols extracted from apples (Malus domestica L.).	2002-04-24	11958609
Comparison of radical scavenging effect, inhibition of microsomal oxygen free radical generation, and serum lipoprotein oxidation of several natural antioxidants.	2002-04-10	11929315
Antioxidative activity and safety of the 50 ethanolic extract from red bean fermented by Bacillus subtilis IMR-NK1.	2002-04-10	11929313
Free radical studies of ellagic acid, a natural phenolic antioxidant.	2002-03-27	11902978
Antioxidant properties of ferulic acid and its related compounds.	2002-03-27	11902973
Chalcones: structural requirements for antioxidant, estrogenic and antiproliferative activities.	2002-03-26	11911276
Free radical scavenging activity of red ginseng aqueous extracts.	2002-03-20	11882354
Free radical scavenging properties of wheat extracts.	2002-03-13	11879046
Antioxidants from the bark of Burkea africana, an African medicinal plant.	2002-03	11933117
Interaction of digoxin with antihypertensive drugs via MDR1.	2002-02-15	11895100
Antagonistic effects of 24R,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 on L-type Ca2+ channels and Na+/Ca2+ exchange in enterocytes from Atlantic cod (Gadus morhua).	2002-02	11854099
Antioxidant capacities of ten edible North American plants.	2002-02	11807968
Antioxidant enzymes and DPPH-radical scavenging activity in chilled and heat-shocked rice (Oryza sativa L.) seedlings radicles.	2002-01-30	11804522
Antioxidant effects of 1,5-anhydro-D-fructose, a new natural sugar, in vitro.	2002-01	11842320
Scavenging of reactive oxygen species by chlorophyllin: an ESR study.	2001-11	11767414
Synthesis and in vitro studies of pyrone derivatives as scavengers of active oxygen species.	2001-11	11765588
Sorbicillinol, a key intermediate of bisorbicillinoid biosynthesis in Trichoderma sp. USF-2690.	2001-10	11758920
Superoxide- and 1,1-diphenyl-2-picrylhydrazyl radical-scavenging activities of soyasaponin beta g related to gallic acid.	2001-10	11758904
[Bepridil inhibition on the delayed rectifier K+ currents in thyroxine induced hypertrophied guinea pig ventricular myocytes].	2001-07	12585077
Is cytotoxic cellular edema real? The effect of calcium ion on water homeostasis in the rat heart.	2001	12213994
Biliary drug lithiasis: dipyridamole gallstones.	1992-11-28	1360065
Evaluation of bepridil efficacy by electrophysiologic testing in patients with recurrent ventricular tachycardia: comparison of two regimens.	1992-04	1390333

Patents

Sample Use Guides

In Vivo Use Guide

Initial dose: 200 mg once a day. Maintenance dose: 300-400 mg once a day.

Route of Administration: Oral

In Vitro Use Guide

In APP-overexpressing HEK293 cells lower Ab38, Ab40 and Ab42 generation was detected after Bepridil treatment (30 uM) for 16 h.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 06:59:39 GMT 2025` Edited by `admin` on `Wed Apr 02 06:59:39 GMT 2025`
Record UNII	755BO701MA
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

1-PYRROLIDENEETHANAMINE, .BETA.-((2-METHYLPROPOXY)METHYL)-N-PHENYL-N-(PHENYLMETHYL)-

Preferred Name

English

BEPRIDIL

Official Name

English

Bepridil [WHO-DD]

Common Name

English

1-(2-(N-BENZYLANILINO)-1-(ISOBUTOXYMETHYL)ETHYL)-PYRROLIDINE

Systematic Name

English

BEPRIDIL [VANDF]

Common Name

English

BEPRIDIL [MI]

Common Name

English

bepridil [INN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QC08EA02